Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Therapeutic Innovation & Regulatory Science
|
May 20, 2022
Health Equity in Pediatric Drug Development: Translating Aspiration into Operation
Morenike Oluwatoyin Folayan, Magda Conway, Carolyn Russo, et al.
The Lancet. Global Health
|
March 28, 2025
Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice
Nina Gobat, Catherine Slack, Stacey Hannah, et al.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV
|
April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
Adeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Therapeutic Innovation & Regulatory Science
|
May 20, 2022
Health Equity in Pediatric Drug Development: Translating Aspiration into Operation
Morenike Oluwatoyin Folayan, Magda Conway, Carolyn Russo, et al.
The Lancet. Global Health
|
March 28, 2025
Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice
Nina Gobat, Catherine Slack, Stacey Hannah, et al.
Contemporary Clinical Trials
|
April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Anna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV
|
April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
Adeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
Page
of 1